Update on Early Combination Therapy with Lastest Monoclonal Antibodies and Antivirals as HIV, HCV, Influenza in Extremely Vulnerable Persons with Sars-Cov-2: A Literature Review and Clinical Experience

Journal Title: Journal of Clinical Medical Research - Year 2025, Vol 6, Issue 1

Abstract

The emergence of new variants of concern in immunocompromised persons with SARS-CoV-2, particularly those with mutations in the spike protein, has complicated treatment strategies. Some Therapies focused only on viral clearance effects and not on major clinical outcomes. As the virus continues to evolve, the development of broad-spectrum therapies, along with personalized approaches to treatment, will be crucial in managing COVID-19 . After the first year period in which several treatments were employed early intervention strategies, including the use of antiretrovirals and monoclonal antibodies, have emerged as promising approaches to mitigate the severity of COVID-19 in fragile individuals and prevent disease progression, hospitalization and death even in recent time with less aggressive SARS-CoV-2 variants. Guidelines, high-quality data for combination treatment exploiting antivirals and neutralizing antibodies do not exist in the outpatient setting, especially in severe immunocompromised individuals. Nevertheless, several studies have attempted to investigate the efect of this approach and although these are often observational studies without control groups, generally no severe adverse reactions from the combination therapy have been reported. The potential efficacy of early combination therapy, based on an antiviral plus a monoclonal antibody, for COVID-19 in severely immunocompromised patients is matter of clinical and literature debate in the scientific word. To date, information concerning the early treatments of COVID-19 using combined therapies has been limited. In this Literature Review we explain the Last variant of concern and the updates on combination therapy for vulnerable persons with Sars-Cov-2.

Authors and Affiliations

Weimer LE1*, Cattari G2, Fanales Belasio E3, Cuccuru E2, Vidili G2

Keywords

Related Articles

Tuberculous Aortitis: An Extremely Rare Cause of Supra Aortic Trunks Stenosis

Aortitis are mainly described in inflammatory disorders such as Takayasu arteritis, giant cell arteritis or Behçet’s disease. Thoracic infectious aortitis such as tuberculous aortitis are currently rare. They are alway...

Metastasis of Differentiated Thyroid Carcinoma: A Descriptive Study of 75 Patients

Introduction: Differentiated Thyroid Carcinoma (DTC) is the most common endocrine malignancy, and is generally of favorable prognosis. However, this latter is significantly worse when initial distant metastasis is presen...

Efficacy of Resin-Modified Glass Ionomer Cement Varnish and Sodium Fluoride Varnish in The Prevention of White Spot Lesions During Fixed Orthodontic Treatment- A Split Mouth Study

Objective: Evaluating efficacy of Resin-Modified Glass Ionomer Varnish and Sodium Fluoride Varnish in prevention of White Spot Lesions (WSLs) during early fixed orthodontic treatment; comparing the incidence of white spo...

Lamelar Ichthyosis

Background: Lamellar Ichthyosis (LI) is a rare hereditary autosomal recessive disease with a defect in chromosome 14q11 which generates defect of transglutaminase-1 (TGM-1) enzyme. Clinical manifestation of IL is initi...

Cementum: Composition, Formation and Regeneration

Cementum is forming a thin layer over the root. Incremental lines of Salter reflect periodic deposition, separating mixed cementum into successive layers. Cementum plays a role in the anchorage of the teeth and adaptativ...

Download PDF file
  • EP ID EP758354
  • DOI https://doi.org/10.46889/JCMR.2025.6102
  • Views 5
  • Downloads 0

How To Cite

Weimer LE1*, Cattari G2, Fanales Belasio E3, Cuccuru E2, Vidili G2 (2025). Update on Early Combination Therapy with Lastest Monoclonal Antibodies and Antivirals as HIV, HCV, Influenza in Extremely Vulnerable Persons with Sars-Cov-2: A Literature Review and Clinical Experience. Journal of Clinical Medical Research, 6(1), -. https://europub.co.uk/articles/-A-758354